156 related articles for article (PubMed ID: 10469313)
1. erbB-2 overexpression but no activation of beta-Catenin gene in extramammary Paget's disease.
Takata M; Fujimoto A; Aoki H; Hatta N; Ooi A; Takehara K
J Invest Dermatol; 1999 Aug; 113(2):258-62. PubMed ID: 10469313
[TBL] [Abstract][Full Text] [Related]
2. Loss of Wnt-5α is associated with an invasive phenotype of extramammary Paget's disease.
Xie L; Hayashida S; Furue M
J Cutan Pathol; 2011 Jul; 38(7):576-80. PubMed ID: 21352264
[TBL] [Abstract][Full Text] [Related]
3. Extramammary Paget's disease: analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein.
Ogawa T; Nagashima Y; Wada H; Akimoto K; Chiba Y; Nagatani T; Inayama Y; Yao M; Aoki I; Ikezawa Z
Hum Pathol; 2005 Dec; 36(12):1273-80. PubMed ID: 16311120
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical study of c-erbB-2 oncoprotein expression in extramammary Paget's disease.
Nishi M; Yoshida H; Setoyama M; Tashiro M
Dermatology; 1994; 188(2):100-2. PubMed ID: 7907892
[TBL] [Abstract][Full Text] [Related]
5. Tumour cells of extramammary Paget's disease do not show either p53 mutation or allelic loss at several selected loci implicated in other cancers.
Takata M; Hatta N; Takehara K
Br J Cancer; 1997; 76(7):904-8. PubMed ID: 9328150
[TBL] [Abstract][Full Text] [Related]
6. Expression of c-erbB-2 oncoprotein in mammary and extramammary Paget's disease.
Wolber RA; Dupuis BA; Wick MR
Am J Clin Pathol; 1991 Aug; 96(2):243-7. PubMed ID: 1713741
[TBL] [Abstract][Full Text] [Related]
7. Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease.
Tanaka R; Sasajima Y; Tsuda H; Namikawa K; Tsutsumida A; Otsuka F; Yamazaki N
Br J Dermatol; 2013 Jun; 168(6):1259-66. PubMed ID: 23360223
[TBL] [Abstract][Full Text] [Related]
8. c-erbB-2 oncoprotein expression in mammary and extramammary Paget's disease: an immunohistochemical study.
Keatings L; Sinclair J; Wright C; Corbett IP; Watchorn C; Hennessy C; Angus B; Lennard T; Horne CH
Histopathology; 1990 Sep; 17(3):243-7. PubMed ID: 2173676
[TBL] [Abstract][Full Text] [Related]
9. Paget's disease of the nipple: a copy number of the genes ERBB2 and CCND1 versus expression of the proteins ERBB-2 and cyclin D1.
Mrhalova M; Kodet R
Neoplasma; 2003; 50(6):396-402. PubMed ID: 14689059
[TBL] [Abstract][Full Text] [Related]
10. p185HER2 overexpression and HER2 oncogene amplification in recurrent vulvar Paget's disease.
Reich O; Liegl B; Tamussino K; Regauer S
Mod Pathol; 2005 Mar; 18(3):354-7. PubMed ID: 15272283
[TBL] [Abstract][Full Text] [Related]
11. Successful human epidermal growth receptor 2-targeted therapy beyond disease progression for extramammary Paget's disease.
Watanabe S; Takeda M; Takahama T; Iwasa T; Tsurutani J; Tanizaki J; Shimizu T; Sakai K; Wada Y; Isogai N; Nishio K; Nakagawa K
Invest New Drugs; 2016 Jun; 34(3):394-6. PubMed ID: 26856856
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the methods used to detect HER2-positive advanced extramammary Paget's disease.
Hirai I; Tanese K; Nakamura Y; Otsuka A; Fujisawa Y; Yamamoto Y; Hata H; Fujimura T; Matsushita S; Yoshino K; Kameyama K; Amagai M; Funakoshi T
Med Oncol; 2018 May; 35(6):92. PubMed ID: 29744813
[TBL] [Abstract][Full Text] [Related]
13. HER2 oncogene amplification in extramammary Paget's disease.
Tanskanen M; Jahkola T; Asko-Seljavaara S; Jalkanen J; Isola J
Histopathology; 2003 Jun; 42(6):575-9. PubMed ID: 12786893
[TBL] [Abstract][Full Text] [Related]
14. Reduced E-cadherin expression correlates with disease progression in Paget's disease of the vulva but not Paget's disease of the breast.
Ellis PE; Cano SD; Fear M; Kelsell DP; Ghali L; Crow JC; Perrett CW; MacLean AB
Mod Pathol; 2008 Oct; 21(10):1192-9. PubMed ID: 18469796
[TBL] [Abstract][Full Text] [Related]
15. Study of neu-protein expression in mammary Paget's disease with and without underlying breast carcinoma and in extramammary Paget's disease.
Meissner K; Rivière A; Haupt G; Löning T
Am J Pathol; 1990 Dec; 137(6):1305-9. PubMed ID: 1701961
[TBL] [Abstract][Full Text] [Related]
16. Concordance of the HER2 protein and gene status between primary and corresponding lymph node metastatic sites of extramammary Paget disease.
Tanaka R; Sasajima Y; Tsuda H; Namikawa K; Takahashi A; Tsutsumida A; Fujisawa Y; Fujimoto M; Yamazaki N
Clin Exp Metastasis; 2016 Oct; 33(7):687-97. PubMed ID: 27289366
[TBL] [Abstract][Full Text] [Related]
17. The role of HER-2/neu oncogene and vimentin filaments in the production of the Paget's phenotype.
Hanna W; Alowami S; Malik A
Breast J; 2003; 9(6):485-90. PubMed ID: 14616943
[TBL] [Abstract][Full Text] [Related]
18. Experiences of trastuzumab plus paclitaxel combination therapy in metastatic human epidermal growth factor receptor 2-positive extramammary Paget's disease: Four cases and a review.
Sekiguchi N; Kubota S; Noguchi T; Fukushima T; Kobayashi T; Kanda S; Koizumi T; Miyake T; Shirai T; Okuyama R
J Dermatol; 2020 Nov; 47(11):1276-1279. PubMed ID: 32706146
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic mutations in extramammary Paget's disease and their clinical relevance.
Kang Z; Xu F; Zhang QA; Wu Z; Zhang X; Xu J; Luo Y; Guan M
Int J Cancer; 2013 Feb; 132(4):824-31. PubMed ID: 22821211
[TBL] [Abstract][Full Text] [Related]
20. MUC5AC expression correlates with invasiveness and progression of extramammary Paget's disease.
Hata H; Abe R; Hoshina D; Saito N; Homma E; Aoyagi S; Shimizu H
J Eur Acad Dermatol Venereol; 2014 Jun; 28(6):727-32. PubMed ID: 23581859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
